Polysaccharide hemostatic powder use as effective as conventional endoscopic therapy for treating peptic ulcer bleeding

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-03-30 14:30 GMT   |   Update On 2023-03-31 07:15 GMT

Polysaccharide hemostatic powder use is not inferior to conventional endoscopic therapy for the treatment of peptic ulcer bleeding suggests a new study published in the Clinical Gastroenterology and HepatologyHemostatic powders have been clinically used in the treatment of gastrointestinal bleeding. We investigated the non-inferiority of a polysaccharide hemostatic powder (PHP), compared...

Login or Register to read the full article

Polysaccharide hemostatic powder use is not inferior to conventional endoscopic therapy for the treatment of peptic ulcer bleeding suggests a new study published in the Clinical Gastroenterology and Hepatology

Hemostatic powders have been clinically used in the treatment of gastrointestinal bleeding. We investigated the non-inferiority of a polysaccharide hemostatic powder (PHP), compared with conventional endoscopic treatments, for peptic ulcer bleeding (PUB).

This study was a prospective multicenter randomized open-label controlled trial at four referral institutions. We consecutively enrolled patients who had undergone emergency endoscopy for PUB. The patients were randomly assigned to either a PHP or conventional treatment group. In the PHP group, diluted epinephrine was injected, and the powder was applied as a spray. Conventional endoscopic treatment included the use of electrical coagulation or hemoclipping after injection of diluted epinephrine.

Results

Between July 2017 and May 2021, 216 patients were enrolled in this study (PHP group, 105; control group, 111). Initial hemostasis was achieved in 92 of 105 patients (87.6%) in the PHP group and 96 of 111 patients (86.5%) in the conventional treatment group. Re-bleeding did not differ between the two groups. In subgroup analysis, the initial hemostasis failure rate in the conventional treatment group was 13.6% for Forrest IIa cases; however, there was no initial hemostasis failure in the PHP group (P=0.023). Large ulcer size (≥15mm) and chronic kidney disease with dialysis were independent risk factors for re-bleeding at 30 days. No adverse events were associated with PHP use.

PHP is not inferior to conventional treatments and could be of use in initial endoscopic treatment for PUB. Further studies are needed to confirm the re-bleeding rate of PHP

Reference:

Da Hyun Jung, Chan hyuk Park, Soo In Choi,Myeongjee Lee, Hee Seok Moon, Jun Chul Park, et al. Comparison of a polysaccharide hemostatic powder and conventional therapy for peptic ulcer bleeding. Published:March 09, 2023DOI:https://doi.org/10.1016/j.cgh.2023.02.031

Tags:    
Article Source : Clinical Gastroenterology and Hepatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News